Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Plants Oversight Flag On Amarin Trade Claim Against Omega-3 Ingredients

Executive Summary

FDA Chief Counsel Rebecca Wood says Amarin's request for an ITC investigation necessarily turns on questions of drug and supplements policy, where it is the expert and authorized agency. If successful, Amarin's move could encourage others to similarly seek alternative forums for action.

Advertisement

Related Content

Compiling Pre-DSHEA Ingredient List Relies On Bridging FDA-Industry Gap
Amarin Makes Flawed Argument In Bid To Drain Omega-3 Market – CRN
Omega-3 Drug Firm’s Trade Complaint Questions US Dietary Ingredient Standards
Off-Label Unleashed? Amarin Win Suggests Firms Still Need Strong Data To Skirt FDA

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

RS121252

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel